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ABSTRACT 
Berry fruits are rich sources of polyphenolic compounds (PCs), which can 
promote health benefits. Anthocyanin concentrations of red raspberry (RR)(Rubus 
idaeus) extracts were determined to be a total of 887.6  ± 262.8 μg/g cyanidin-3-
sophoroside  (C3S) equivalents with C3S being the most prevalent. Ellagitannin 
analysis by MALDI-TOF indicated sanguiin H-6 and lambertianin C were the major 
ellagitannins present in RR. To explore the efficacy of RR in modulating diabetes, 
seven  type 2 diabetes mellitus (T2DM) and two pre-diabetic patients  were given  
drinks delivering one RR serving (123 g) per day in a smoothie for two weeks.   
Blood samples were drawn at baseline (BSL) and post-feeding (PF) days.  The 
samples were analyzed for phenolic metabolites, and for both inflammation and 
insulin resistance biomarkers. Two urolithin conjugates, i.e. urolithin A glucuronide 
(Uro-A glur) and urolithin A sulfate (Uro-A sulf) were found in 7 of the 9 patients’ 
plasma samples at nanomolar concentrations on PF day whereas anthocyanin-
derived metabolites such as protocatechuic acid (PCA) and 3,4-
dihydroxyphenylacetic acid (DOPAC) were present at higher but not statistically 
significant  levels on both groups at PF day  when compared to BSL. Results 
indicated significant reductions in hsCRP (p= 0.01), and on insulin resistance where 
a statistical trend on HOMA-IR (p=0.0584) for T2DM patients was seen. DOPAC, a 
metabolite from anthocyanin and quercetin consumption in RR, when incubated at 1-
100 µM did not stimulate insulin secretion in INS-1 rat pancreatic cells. Increases 
and decreases were observed on the cytokines analyzed by multiplex assay, yet, 
none was significant on either group. This study demonstrates the potential of RR to 
modulate levels of biomarkers of inflammation and insulin resistance in diabetic 
prediabetic patients .
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CHAPTER 1.  LITERATURE REVIEW 
1.1. Diabetes Overview 
  The prevalence of type 2 diabetes globally is a concern and a significant 
burden due to its many health complications [1]. Diabetes is one of the most 
common chronic conditions and was the seventh leading cause of death in the 
United States (US) as of 2015 [2]. According to the International Diabetes 
Federation, 382 million people were affected by this disease in 2013 and the 
prevalence of the disease is expected to rise to 592 million by 2035 [3].  The World 
Health Organization (WHO) on its 2015 report discloses that cardiovascular diseases 
(CVD) are the main cause of death globally and prevalence of diabetes among 
adults over 18 years of age has increased from 4.7% in 1980 to 8.5 % in 2014. 
Projections indicate diabetes will still be the 7th leading cause of death in 2030 [4].   
In the US, recent data indicate that 30.3 million people of all ages had the condition 
in 2015  (~ 9.4 % of the population) of which 30.2 million were adults aged 18 or 
older and of which 7.2 million were not aware or did not report they had diabetes [2].  
An additional 84.1 million adults aged 18 years or older had prediabetes and nearly 
half (48.3%) of the adults aged 65 or older were prediabetics [2]. Regardless of 
technical and technological progress achieved to date, which has evolved with 
therapeutic tools and public health plans, it has not been possible to stop the 
progression of diabetes along with its complications [5]. Cardiovascular diseases are 
the major cause of death and disability among diabetic patients [6]. Diabetic vascular 
complications constitute a serious problem in diabetes which leads to additional 
functional decline of different organs and cause micro- and macro-angiopathy [7].      
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Diabetes as a disease has been recognized for several thousand years in 
various medical systems and cultures ranging from ancient Egypt, to classical India, 
China, Greece and Rome. Its meaning in Sanskrit: Madhumedha, shares the 
descriptive denotation as its Latin version, diabetes mellitus, which is sweet urine. In 
India, for instance, a classical diagnostic test was performed by pouring the patient’s 
urine on the ground close to an ant colony and  if ants swarmed the urine, the patient 
was deemed a diabetic [8]. 
1.1.1. Diabetes Types, Etiology, and Symptoms 
Diabetes mellitus is a metabolic disorder marked by elevated levels of blood 
glucose  (hyperglycemia) with disturbances on carbohydrate, fat and protein 
metabolism as a result of  insufficient or inefficient insulin secretion, action, or both 
[9, 10]. Characteristic symptoms that accompany the disease are thirst, polyuria, 
blurred vision, and weight loss with severe symptoms leading to ketoacidosis or non-
ketotic hyperosmolar state which can derive in stupor, coma or even death when not 
treated properly [10]. Based on the pathogenesis or etiology of the disease, diabetes  
can be classified in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus 
(T2DM), other specific types of diabetes and gestational diabetes. T1DM makes up 
5-10% of the diabetic patients [11]. It is a less common form of the disease and is 
associated with autoimmune destruction of the pancreatic β-cells and therefore 
complete or near-total insulin deficiency.  T1DM has been further sub-classified as 
Type 1A and Type 1B. Type 1A or autoimmune diabetes can sometimes be 
associated with other autoimmune conditions that include Hashimoto’s thyroiditis, 
Addison’s disease, vitiligo and others [12].  Because genetic factors alone do not   
predict the development of type 1 diabetes, therefore, environmental factors that 
may be involved  include viral infections, toxins from food, cow milk intake during 
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childhood (instead of breast feeding) or vitamin D deficiency [13]. Type 1B or 
idiopathic diabetes on the other side, does not present an autoimmune basis to β-cell 
destruction and patients who suffer this type of diabetes are mainly of African or 
Asian ancestry [11]. T2DM, on the other hand, accounts for 90-95% of diabetic 
patients and its onset is dictated by a typically relative, not absolute, β-cell failure to 
produce insulin. This production becomes insufficient and leads to insulin resistance. 
Individuals with T1DM or T2DM have an increased risk of developing a number of 
chronic diseases, which affect the heart and blood vessels, eyes, kidneys and 
nerves often referred as microvascular complications. Furthermore, effects on the 
heart and blood vessels can cause fatal complications such as coronary artery 
disease and stroke which constitute the macrovascular complications that 
accompany the disease, with cardiovascular disease being the number one cause of 
death in people with diabetes mellitus [14].  
Other specific types of diabetes include maturity-onset diabetes of the young 
(MODY) which is characterized by early age (< 25 yrs.) onset and autosomal 
dominant mode of inheritance. The cause of hyperglycemia in MODY is due to 
mutations in certain genes yet insulin resistance appears to be extremely rare [15]. 
Six types of MODY have been described and affect specific genes such as HNF-4α, 
Glucokinase, HNF-1α, IPF-1, HNF-1β, NeuroDI or BETA2 and this modality of 
diabetes can encompass 2-5 % of all T2DM cases [13].       
Other types of diabetes can occur due to genetic defects of insulin action, due 
to diseases of the exocrine pancreas (pancreatitis, small pancreatic carcinomas) and 
in patients with cystic fibrosis, diabetes is the most common comorbidity occurring in 
20% of adolescents and 40–50% of adults [16]. Endocrinopathies on which 
excessive production of certain hormones such as cortisol, glucagon and 
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catecholamines is present, the use of certain drugs and chemicals, i.e. rat poison, 
pentamidine, glucocorticoids and infections with viruses like rubella, are among other 
reasons that may cause diabetes [17, 18].     
Gestational diabetes mellitus (GDM) is also a fairly common form of this 
disease and it is defined as a clinical condition observed in pregnant women as a 
result of insulin resistance and subsequent high blood glucose levels but also due to 
prevalence of overweight and obesity in women of childbearing age [19]. This state 
develops as a result of insulin action being blocked, presumably by placental 
hormones [20, 21].  
Normally, gestational diabetes ends after the baby is born; however, women 
with gestational diabetes are at high risk of having the same condition in following 
pregnancies and are at higher risk of developing T2DM later in life but risk for T1DM 
is also present [22].  
1.1.2. Disease Diagnosis 
Several criteria can be used to diagnose whether an individual suffers from 
diabetes. One of them is through hemoglobin A1c (HbA1C). HbA1C is a test that 
reflects long-term blood glucose [23]. Hemolysates of red blood cells can be 
chromatographed, resulting in three or more small peaks named hemoglobin A1a, 
A1b, and A1c. These peaks (referred to as “fast” peaks) are eluted before the main 
hemoglobin A peak, and are formed by the irreversible attachment of glucose to     
hemoglobin in a two-step reaction [24]. The percentage of hemoglobin glycosylated  
depends on the average glucose concentration the red cell is exposed to over time, 
and due to the average 4-month life of a red cell, the percentage of glycosylated 
hemoglobin indicates accurately the degree of blood sugar control over the 
preceding weeks. Hemoglobin A1c is quantifiably the largest peak so that it is mostly 
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selectively measured, but occasionally all “fast" hemoglobins can be measured. An 
HbA1C ≥ 6.5 % will deem a positive diagnostic for diabetes. Another way is through 
plasma glucose criteria by measurement of either fasting plasma glucose (FPG) or 
the 2-h plasma glucose (2-h PG) value by means of an oral glucose tolerance test 
(OGTT) after taking a 75-g glucose containing drink. FPG ≥126 mg/dL (7.0 mmol/L) 
or 2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT will also indicate the person 
being evaluated is indeed a diabetic [25]. 
 “Prediabetes” is the term used for individuals with impaired fasting glucose 
(IFG, defined as FPG levels 100–125 mg/dL or 5.6–6.9 mmol/L) and/or impaired 
glucose tolerance (IGT, defined as 2-h PG after 75-g OGTT levels 140–199 mg/dL or 
7.8–11.0 mmol/L). These conditions indicate pre-disposition for future development 
of diabetes. IFG and IGT should be considered risk factors for diabetes and CVD, 
and are associated with obesity, dyslipidemia (high triglycerides and/or low HDL 
cholesterol), and hypertension [25], a cluster of conditions similar as those observed 
on the metabolic syndrome (MS) [26]. Besides IFG and/or IGT, individuals with an 
A1C of 5.7–6.4% are considered at increased risk for diabetes and CVD and should 
adopt effective strategies to lower their risks [25].  
1.2. Reactive Oxygen Species and Insulin Resistance 
  Oxidative stress and oxidative damage to tissues are a habitual result of 
chronic diseases such as atherosclerosis, diabetes and rheumatoid arthritis [27].  
Oxidative stress denotes an imbalance between cellular reactive oxygen species 
(ROS) and antioxidants, where the former have an advantage. Examples of ROS 
include the superoxide anion (•-O2), hydrogen peroxide (H2O2), hydroxyl radical 
(OH), singlet oxygen (1O2) and ozone (O3). Growing evidence suggests that 
oxidative stress has a causative role in insulin resistance [28]. To illustrate this, a 
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reduction on mitochondrial hydrogen peroxide emission when treating rats with a 
mitochondrial-targeted antioxidant or by overexpression of catalase in mouse 
skeletal muscle aided on preserving insulin sensitivity [29]. 
  Highly reactive molecules include ROS and reactive nitrogen species (RNS). 
Among these reactive molecules superoxide (•O-2), nitric oxide (•NO), and 
peroxynitrite (ONOO-) are the most widely studied and are relevant in the diabetic 
cardiovascular complications. Superoxide (•O-2) is produced by one electron 
reduction of oxygen by different oxidases such as dihydro-nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (NOX), xanthine oxidases, 
cyclooxygenase and also by mitochondrial electron transport chain during normal 
oxidative phosphorylation, a fundamental process for generation of  adenosine 
triphosphate (ATP) [30]. Five major pathways become activated because of 
increased production of superoxide, all of which are involved in the pathogenesis of 
diabetic complications: the polyol pathway flux, increased formation of advanced 
glycation end-products (AGEs), increased expression of the receptor for AGEs and 
its activating ligands, activation of protein kinase C (PKC) isoforms and over activity 
of the hexosamine pathway [31].   
  The polyol pathway is a pathway of glucose metabolism regarded as a key 
component in the pathogenesis of diabetic retinopathy, refractive changes and 
cataract formation  in diabetic patients [32].The enzyme aldose reductase (AR) plays 
an important role in the polyol pathway as it reduces toxic aldehydes in the cell to 
inactive alcohols [33].  However, when intracellular glucose concentration becomes 
too high, sorbitol reduction from glucose by AR occurs as well and does this by using 
NADPH as a cofactor. NADPH is an important cofactor for the regeneration of 
antioxidants, and becomes reduced to glutathione (GSSG). A second enzyme, 
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sorbitol dehydrogenase oxidizes sorbitol to fructose, using nicotinamide adenine 
dinucleotide (NAD+) as a cofactor [32]. Sorbitol is an alcohol that is polyhydroxylated  
and strongly hydrophilic, and therefore does not diffuse easily through cell 
membranes leading to intracellular accumulation with possible osmotic 
repercussions[34]. 
Advanced glycation end products (AGEs) or glycotoxins, are highly oxidant 
compounds which can lead to diabetes and several other chronic diseases [35-37]. 
AGEs form by a nonenzymatic reaction between reducing sugars and free amino 
groups of proteins, lipids, or nucleic acids, a reaction also known as the Maillard or 
browning reaction [38]. Normal metabolism results in the formation of AGEs, 
however, when levels become too high in tissues and the circulation, they promote  
pathogenic effects through oxidative stress and inflammation. Modern diets with 
abundant heat-processing result in high levels of AGEs. Dietary advanced glycation 
end products (dAGEs) are recognized as a source of increased oxidant stress and 
inflammation, which are directly related to the recent epidemics of diabetes and 
cardiovascular disease [39]. A study with 21 patients on a high-AGE diet for 1 week 
resulted in weight gain and impaired insulin sensitivity [40]. These effects happen 
due to the binding of AGEs with cell surface receptors (such as the receptor of AGE, 
RAGE) or cross-linking which results in a disruption of the molecular conformation of 
proteins, lipids and nucleic acids and can lead to altered function [41]. Examples of 
widely studied AGEs are Nε-carboxymethyllysine (CML) [42] and the very reactive 
derivatives of methyl-glyoxal (MG) (i.e. hydroimidazolone) [43].  
The diacylglycerol (DAG)-PKC pathway is one of the most studied pathways 
in cellular signaling induced by diabetes [44]. The protein kinase C (PKC) molecule 
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belongs to the serine/threonine kinase family, which catalyzes phosphorylation of 
proteins involved in signal transduction. Conventional and novel PKC isoforms are  
upregulated by (DAG) [45]. In diabetes, total DAG levels are elevated in vascular 
tissues such as those of retina, aorta, heart and renal glomeruli, and in nonvascular 
tissues such as liver and skeletal muscles, yet this is not the case in the central 
nervous system and peripheral nerves [46]. In vitro studies demonstrate DAG levels 
increase in a time-dependent manner as glucose levels rise from 5.5 to 22 mM in 
aortic endothelial cells, retinal pericytes, smooth muscle cells and renal mesangial 
cells [46]. 
PKC has been linked to vascular alterations which include increases in 
contractility, endothelial permeability, extracellular matrix synthesis, angiogenesis, 
cell growth and apoptosis, and cytokine activation and inhibition as well as leukocyte 
adhesion[47].   
Several groups have proposed that flux through the hexosamine synthesis 
pathway (HSP) could have a role as a cellular nutrient sensor and be involved in the 
development of insulin resistance and the vascular complications of diabetes [48]. 
The HSP is a somewhat small component of the glycolytic pathway, accounting for ~ 
3% of total glucose utilized [49]. The mode of action seems to be transcriptional 
regulation, possibly regulated by  N-acetylglucosamine in O-linkage (O-GlcNAc) 
modification of transcription factors [48]. Incubation in high glucose, or with GlcNAc 
or overexpression of the first and rate limiting enzyme in HSP, glutamine: fructose-6-
phosphate (F-6-P) amidotransferase (GFAT), enhanced the activation of the 
plasminogen activator inhibitor 1 (PAI-1) promoter, as well as stimulated the cytokine  
transforming growth factor beta (TGF-β) expression in mesangial cells or aortic 
endothelial cells [50, 51]. 
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Beta cells have a high metabolic activity due to glucose oxidation-dependent 
stimulus secretion coupling, which derives in formation of ROS. With low expression 
of anti-oxidative enzymes such as catalase, super oxide dismutase (SOD) and 
glutathione peroxidase[52], β-cells are vulnerable to ROS and in both T1DM and 
T2DM, increased ROS formation results in β-cell loss [53].  ROS involvement in the 
progression of insulin resistance as well as pancreatic β-cell dysfunction has been  
demonstrated [54] and it was previously reported that ROS disrupted insulin-induced  
cellular redistribution of insulin receptor substrate-1 (IRS-1) and phosphatidylinositol 
3-kinase (PI3-K), and thus impaired insulin-induced glucose transporter type 4 
(GLUT4) translocation in 3T3-L1 adipocytes [55, 56].  Treatment with antioxidants 
such as N-acetyl L-cysteine and taurine appeared to prevent hyperglycemia-induced 
insulin resistance in vivo [57]. Acute and chronic administrations of the antioxidant α-
lipoic acid improved insulin resistance in T2DM patients, advocating a role for ROS 
in the development of insulin resistance [58, 59].     
1.3. Inflammation and Diabetes     
Chronic inflammation is a crucial factor in the development of insulin 
resistance and T2DM (6). The presence of inflammation in metabolic disorders like 
diabetes mellitus has been studied in recent years and the inflammatory reaction is 
mediated by acute phase proteins and cytokines. The acute phase response is a 
systemic reaction to tissue injury and infection. This response leads to macrophage 
release of cytokines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor 
(TNF) which reach the liver and stimulate this organ to produce acute phase proteins 
(APPs) [60] . The two main APPs are C-reactive protein (CRP) and serum amyloid A 
(SAA) [61]. The term cytokine refers to an abundant number of cellular proteins that 
mediate pleiotropic (stimulation of numerous functions on many cell types) pro-
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inflammatory and anti-inflammatory effects. In the case of diabetes, the release of 
such APPs and cytokines can have either diabetes-preventing or diabetes-promoting 
effects [62]. 
A distinctive feature of T2DM is the combination of both insulin resistance and 
pancreatic β-cell dysfunction, which leads to hyperglycemia at various levels. Some  
mechanisms identified to contribute to this condition include oxidative stress, nuclear  
factor kappa β (NF-κB) dependent production of pro-inflammatory cytokines, Toll-like 
receptors {TLR (Figure 1.1.)]) expression, and inflammasome [1][63-65]. T2DM has 
a genetic element but other factors such as over-nutrition (excessive food intake), 
lack of physical activity, but also exogenous factors such as medications, can 
intervene. Inflammatory pathways are a mean for T2DM to develop and as such, 
provide an important setting to develop treatments to prevent or control diabetes. 
NF-κB is considered the main control regulating the synthesis of many proteins 
critical for the activation and maintenance of inflammation [9]. IL-1 is a pleiotropic 
cytokine whose biologic effects include upregulated expression of adhesion 
molecules, cytokines and arachidonic acid metabolites as well as enhanced 
neutrophil accumulation, fibroblast proliferation and angiogenesis. The IL-1 family 
consists of two pro-inflammatory cytokines: IL-1α, IL-1β and a naturally occurring 
anti-inflammatory agent, the IL-1receptor antagonist (IL-1RA). IL-1β induces intra 
islet inflammation which in turn diminishes β-cell function and survival and more 
specifically, IL-1β plays a significant role on T2DM onset and insulin resistance [66]. 
TNF-α and IL-1β act as inducers of NF-kB activation producing elevated reactive 
oxygen species (ROS) levels. This suggests the involvement of ROS as common 
mediators of NF-kB activation [67]. Mature IL-1β is associated with the NOD 
(nucleotide oligomerization domain) -like receptor pyrin domain containing protein 3 
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(NLRP3) inflammasome subunit [1][68, 69]. NLRP3 is present in the pathogenesis of 
T2DM, Alzheimer’s and amyotrophic lateral sclerosis [39].  
Inflammation is a protective response of the host to infections and tissue 
damages and includes a series of reactions such as vasodilation and recruitment of 
immune cells and plasma proteins to the site of infection or injury. Reactive oxygen 
species (ROS) generated from deteriorated mitochondria activate NLRP3 
inflammasome [70], and the latter promotes other inflammatory cytokines such as IL-
18 and IL-33 which are involved in the pathogenesis of diabetes [71].  
1.4. Insulin Resistance and β-cell Apoptosis 
Increased insulin resistance (IR) is considered to be the major 
pathophysiological cause for T2DM in patients. In healthy individuals, insulin 
increases glycogen production in the liver, lipid synthesis by adipose tissue, and 
glucose uptake in muscle [72].  
 
Figure 1.1. The pro-inflammatory response of islet macrophages in type 2 diabetes.  
(fig. cont’d) 
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“TLR2-and TLR4-activating PAMPs (LPS, lipoproteins) and DAMPs (HSP60, HSP70,  
HMGB1, hyaluronan, saturated fatty acids) are increased systemically in type 2 
diabetes. Local islet-derived TLR2 and/or TLR4 DAMPs may also be increased and 
may include HMGB1, necrotic cell debris and IAPP deposits. These ligands may act 
on islet macrophages via TLR2 and/or TLR4, upregulating cytokine secretion (IL-6, 
TNF-α), with deleterious effects on β-cell insulin secretion and α-cell glucagon 
secretion. Islet-derived (IAPP, endocannabinoids) or systemically elevated (glucose, 
saturated fatty acids) NLRP3 stimuli also act on macrophages to facilitate cleavage 
of proIL-1β to mature IL-1β and secretion of IL-1β. IL-1β then acts in a paracrine 
manner, together with elevated IL-6 and TNF-α, to impair β-cell insulin secretion and 
cause dysregulated α-cell glucagon secretion. A potential role for macrophage-
derived IL-1α also exists but has not been studied. AP-1, activator protein 1; DC, 
dendritic cell” [65].    
 
  IR is many times the result of reduced sensitivity of the insulin receptor that is 
composed of two insulin-binding α-subunits and two β-subunits [73]. A reduction of 
40 % β-cell mass in young adults is enough to induce hyperglycemia, a hallmark of 
diabetes [74]. Problems with insulin secretion and action derive in numerous 
abnormalities in T2DM such as hyperglycemia due to disruption of insulin-stimulated 
glucose uptake, uncontrolled hepatic glucose production and dyslipidemia where 
impaired homeostasis of fatty acids, triglycerides and lipoproteins are usually 
observed [75].    
Significant evidence suggests that obesity activates inflammatory signaling 
pathway and can induce endoplasmic reticulum (ER) stress with particular activation 
of serine/threonine kinases IκB kinase (IKK) and c-jun amino terminal kinase (JNK) 
[76]. Figure 1.2., shows how IKK and JNK pathways are activated in response to 
stimuli during metabolic dysregulation. This includes ligands for TNF-α, IL-1, Toll, 
RAGE, ROS and ER stress, ceramide, as well as several PKC isoforms [9].  JNK 
plays a central role in the cell stress response and recent evidence points at JNK1 
and JNK2 isoforms as promoters of obesity and insulin resistance, whereas JNK3  
activity seems to protect from excessive adiposity. Moreover, evidence indicates that  
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JNK activity can promote cell tolerance to the stress associated with obesity and 
type-2 diabetes in certain cell types at specific disease stages [77]. Even though IR  
is characteristic of T2DM, disease progression depends on insufficient insulin 
production, in all probability as result of reduced β-cell mass due to apoptosis [78].  
 
Figure 1.2. “The insulin action can be inhibited by inflammatory signaling pathways. 
Inflammation and stressful stimuli activates c-jun amino terminal kinase (JNK), IκB 
kinase (IKK), and protein kinase Cθ (PKC-θ) which result in inhibition of insulin 
signaling. The activation of sterol regulatory element binding protein-1c (SREBP-1C), 
upstream stimulatory factor 1 (USF1), and liver X receptor (LXR) induces fatty acid 
synthesis”[9]. 
 
Himsworth and Kerr were the first to recognize the relation between insulin 
resistance and diabetes in 1939 based on blood glucose responses to exogenous 
insulin [79]. They demonstrated that obese patients with diabetes could be classified 
into two categories: those who were insulin-sensitive (T1DM) and those who were 
insulin-resistant (T2DM) [79].Current information advocates at IR being an acquired 
issue vastly related to unhealthy lifestyles with impaired insulin secretion being the 
major genetic factor [80].  
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     Overweight and obesity increase risk for diabetes and CVD, mainly through IR 
[81]. Weight loss has been proven beneficial in obese individuals with IR, yet, the 
same benefits have not been observed in overweight individuals [81]. McLaughlin et 
al. [81] administered a hypocaloric diet for 14 weeks and 2 weeks of weight 
maintenance to a group of healthy volunteers with BMI 25-29.9 kg/m2. They 
performed detailed metabolic phenotyping which included insulin-mediated-glucose 
disposal and fasting/daylong glucose, among others. To gauge adipose cell size on 
the individuals, subcutaneous fat biopsies were performed as well. The metabolic 
phenotype provides a description of the metabolic state of an individual and derives 
from the genetic and environmental (diet, lifestyle, gut microbial activity) 
contributions under a specific set of circumstances [82]. The researchers found the 
patients had weight loss (4.3 kg) which yielded significant improvements in insulin 
resistance and all cardiovascular risk markers except glucose, HDL-C, and LDL-C. 
They reported that insulin sensitivity was greater among those with < 2 vs > 2 
cardiovascular risk factors at baseline. Decrease in adipose cell size and waist 
circumference, but not weight or body fat, independently predicted improvement in  
insulin resistance [81]. Their results suggested that IR overweight individuals, 
regardless of the absence of potential established CVD risk markers, can yield 
benefits from dietary weight loss, and that both,  reduction in adipose cell size and 
waist circumference, are better predictors of metabolic response than weight loss per 
se [81]. 
      There is controversy on regards to the role of factors such as obesity, insulin 
resistance, insulin secretory dysfunction, and excess hepatic glucose production in 
the development of T2DM. Lilioja et al. [83]  conducted a prospective study to 
determine which of these factors predicted the development of the disease in a 
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group of Pima Indians. The Pima Indians, a Native American population in Arizona, 
have the highest reported prevalence of diabetes of any population in the world [84].  
Researchers assessed potential development of the disease through oral and 
intravenous glucose-tolerance tests, and a hyperinsulinemic-euglycemic clamp 
study. These were performed in 200 nondiabetic Pima Indians (87 women and 113 
men; mean [±SD] age, 26 ±6 years). The subjects were followed yearly thereafter for 
an average of 5.3 years. Their results showed the development of diabetes in 38 
subjects during follow-up. Obesity, insulin resistance (independent of obesity), and 
low acute plasma insulin response to intravenous glucose (with the degree of obesity 
and insulin resistance taken into account) were predictors of T2DM. The six-year 
cumulative incidence of T2DM was 39 percent in persons with values below the 
median for both insulin action and acute insulin response, 27 percent in those with  
values below the median for insulin action but above that for acute insulin response,  
13 percent in those with values above the median for insulin action and below that  
for acute insulin response, and 0 in those with values originally above the median for 
both characteristics. Through these results, the researchers concluded IR was a 
major risk factor for the development of T2DM with low acute insulin response to 
glucose being an additional but weaker risk factor [83]. 
     Besides being a storage place for fat, adipocytes perform an important 
endocrine role by secreting several relatively recently identified hormones and 
cytokines [80]. These molecules are hypothesized to play relevant functions in 
insulin action and metabolism of glucose and fat. The factor resistin, for instance, is 
an adipocyte-secreted peptide hormone that has been observed to impair glucose 
homeostasis and insulin action in rodents [85]. Work done previously shows 
circulating resistin levels are increased in diabetic rodent models and that the 
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administration of antiresistin antibody improves blood glucose and insulin sensitivity 
[85].  
     Thiazolidinediones that improve insulin sensitivity reduce resistin production 
[86] yet, the role of resistin in humans is not clear since reports of resistin protein 
levels and gene expression in obese humans remain inconsistent [87-89]. 
     The hormone adiponectin is another promising and interesting bridge between 
IR and increased fat tissue. Studies show adiponectin plasma levels decrease 
proportionally with the accumulation of adipose tissue, especially visceral one [90] as 
well as with the development of insulin resistance and T2DM. Administration of 
adiponectin to mice enhanced insulin sensitivity and glucose tolerance, reduced food  
intake, lowered plasma glucose and triglyceride levels, and increased free fatty acids 
(FFA) oxidation in muscle [91-93]. 
      Predisposition of some individuals to IR and T2DM from birth due to 
consistent IR has been found in first degree relatives and offspring of patients with 
T2DM. Hence, the underlying view is that IR is at least partially determined by a role 
played by genetic traits [94].  Warram et al. [95]  reported that IR predicts the 
development of type 2 diabetes in the offspring of diabetic parents. This is reflected 
in young and healthy offspring of diabetic parents who exhibit IR and impaired 
muscle insulin signaling and glycogen synthesis many years before onset of evident 
T2DM [96]. Recent large-scale genome-wide association (GWA) studies, however, 
have failed to detect  polymorphisms of genes involved in insulin action or insulin 
signaling which contribute to the development of T2DM [97]. Contrary to that, several 
genes thought to be involved in the control of insulin secretion have shown 
polymorphisms that grant minor but statistically significant increased susceptibility to 
T2DM [97]. Therefore, reports lead to speculate that IR in offspring of diabetic 
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mothers to some unknown degree may obey to the presence of obesity and/or mild 
glucose intolerance during pregnancy itself, and not necessarily to genetics [98]. 
Vaag [98] suggests that even though many genes involved in the development of 
T2DM remain to be discovered, the chance of ‘genetic insulin resistance’ due to 
intrauterine programming should remain open. 
      Data from several sources points out that insulin-like growth factor-1 (IGF-1) 
seems to play a role in progressive decline in insulin sensitivity observed in T2DM 
[99]. Obese individuals display abnormalities in the growth hormone (GH)/IGF-1 axis  
resulting in low basal GH levels and reduced IGF-1 levels compared with nonobese 
individuals. These levels are improved when weight loss is attained [100, 101]. 
In higher organisms, GH controls growth by regulating IGF-1 concentrations, but 
another major function of GH is to provide a mechanism for surviving periods of food 
deprivation. GH stimulates lipolysis, providing FFAs and glycerol as substrates for 
energy metabolism, and also inhibits insulin-induced suppression of hepatic 
gluconeogenesis. These effects counteract insulin action and reduce the need for a 
dietary source of carbohydrate [102]. 
     IGF-1 shares 48% amino acid sequence identity with proinsulin. IGF-1 
enhances insulin sensitivity in both experimental animals and human subjects and its 
primary insulin-sensitizing action is believed to be mediated through skeletal muscle 
[103]. A problem, however, when interpreting human studies of IGF-1 has been that, 
in addition to enhancing insulin action, it also suppresses GH secretion.   This fact 
has made difficult to determine the relative roles of the direct actions of IGF-1along 
with those mediated by suppression of GH [103]. 
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     Besides IR, defects in pancreatic β-cell function constitute one of two major 
pathophysiologic abnormalities that lie behind most cases of T2DM [104]. Genetic 
and epigenetic components have been identified. 
     While the epigenome may change due to environmental exposure, variations 
may also be stable and inherited, making epigenetics a hypothetical important 
pathogenic mechanism. Impaired intrauterine environment from an environment that 
may alter the pancreatic islet epigenome and possibly affect β-cell function and 
diabetes pathogenesis is shown in human and animal studies. Resulting low birth 
weight, increased risk for postnatal metabolic disease, decreases in β-cell 
proliferation mass, and insulin secretion are some documented epigenetic 
modifications occurring at key β-cell genes [105, 106]. Epigenetic mechanisms 
include DNA methylation and histone modifications which can be active during fetal, 
postnatal and adult life [107].  
Many physiologic stressors may influence β-cell function in the environment of 
metabolic overload and IR commonly found in human obesity-linked T2DM. 
Pathologic conditions associated with beta cell demise include ER stress, metabolic 
and oxidative stress, amyloid plaques, inflammation and disruption of islet 
integrity/organization (Figure 1.3.) [104]. 
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Figure 1.3. Stressors on the β-cell in the pathogenesis of T2DM [104]. 
     Apoptosis or programmed cell death, is a complex biological process where 
events such as cell shrinkage, chromatin condensation, DNA fragmentation and 
finally disassembly into vesicles called apoptotic bodies are manifested [108].  
Deposits of amyloid are characteristic of  islets in T2DM [109] . These deposits are 
derived from  amylin or  islet amyloid polypeptide (IAPP) [110]. Excess nitric oxide 
(NO) production, when obtained through inducible nitric oxide synthase (iNOS), has 
implications in insulin resistance, markedly when obesity is present [111].  This may 
be explained by hyperglycemia and hyperlipidemia, as both conditions are common  
to T2DM, and can induce iNOS expression in islet tissue in healthy animals [112]. 
1.5. INS-1 Cells and Insulin Secretion 
       Glucose represents the main physiological stimulus for the secretion of insulin 
from pancreatic β-cells. As glucose enters the cells through glucose transporter 2 
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(GLUT2), it becomes phosphorylated to glucose-6-phosphate by the enzyme 
glucokinase and is then metabolized to generate ATP. Production of ATP induces 
the closure of ATP-sensitive K+ channels (KATP) which induces membrane 
depolarization and the opening of voltage-dependent Ca2+ channels (VDCCs). This 
results in an increase in cellular Ca2+ influx and serves as a primary driver of the 
insulin secretory mechanism [113, 114]. 
 Insulinoma-derived INS-1 and INS-1E cells are trustworthy beta-cell 
surrogates which display electrophysiological properties, secretagogue-induced 
electrophysiological activity, Ca2+ signaling, stimulus-secretion coupling and 
sulfonylurea and diazoxide-sensitivities similar to those found in native islets [115]. 
Glucose stimulated insulin secretion (GSIS) is important for the control of metabolic 
fuel homeostasis and defective GSIS is a critical part of β-cell failure that leads to 
T2DM [116]. Geniposide, an iridoid glucoside derived from Gardenia jasminoides or 
gardenia fruit [117] was found to enhance GSIS in response to the stimulation of low 
or moderately high concentrations of glucose, and promoted glucose uptake and 
intracellular ATP levels in INS-1 cells. Experiments performed by Liu et al. [109] 
demonstrated that geniposide modulated pyruvate carboxylase expression and the 
production of intermediates of glucose metabolism suggesting this compound has 
potential to improve insulin secretion in β-cells challenged by high glucose 
concentrations. Kittl et al. when using quercetin to test insulin secretion on INS-1 
cells [108], concluded that quercetin acutely stimulated insulin release, presumably 
by short-term KATP channel inhibition and simultaneous short-term stimulation of 
voltage-sensitive Ca2+ channels. 
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1.6. Economic Burden of Diabetes 
Diabetes along with its complications represents a substantial economic loss 
to not only people who suffer from it, but also to their families, health systems and 
national economies through medical costs and loss of work and wages [118]. Recent 
systematic reviews estimate the world’s annual cost of diabetes to be more than US 
$827 billion [119, 120]. The International Diabetes Federation (IDF) estimates that 
total global health-care spending on diabetes more than tripled between 2003 to 
2013 as a result of increases in the number of people with the disease and increases 
in per capita diabetes spending [121].  The medical costs associated with T2DM 
continue to increase and there is a dire need for new options to treat the disease. 
1.7. Therapeutic Approach 
       The major classes of oral antidiabetic medications include biguanides such as  
metformin, sulfonylureas, meglitinide, thiazolidinediones (TZD), dipeptidyl peptidase 
4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, and α-
glucosidase inhibitors [122]. Even though they can be effective in ameliorating 
symptoms present in diabetes, a downside to these agents is that they may cause a  
myriad of disturbances or side effects. These disturbances include gastrointestinal 
ones such as diarrhea, nausea, and dyspepsia and may also be contraindicated in 
patients with renal failure [64].  
1.8. Dietary Approach 
       An important recommendation by the American Association of Clinical 
Endocrinologists consists of consuming a plant-based diet which is high in fiber, low  
in carbohydrates and calories, and high in phytochemicals/antioxidants [123].      
       Phenolics encompass a numerous group of natural and anthropogenic 
compounds. Most natural phenolic compounds are secondary metabolites in plants 
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and trees, therefore, being present in foods but are also used as supplements, 
additives and nutraceuticals. Chinese physicians, for instance, have been using plant 
phenolics for many years to treat various diseases and disorders. Currently, more 
than 8,000 phytochemicals are known of which more than 5,000 are flavonoids.   
       These phytochemicals can be divided into at least 10 types depending on 
their basic structure and those are: phenols, phenolic acids, hydroxycinnamic acids, 
coumarins/isocoumarins, naphthoquinones, xanthones, stilbenes, anthroquinones, 
flavonoids and lignins [124]. Flavonoids can further be divided into flavones, 
flavonols, flavanones, flavan-3-ols, anthocyanidins and isoflavones. Phenolics are 
able to act as antioxidants through several routes.  
      The hydroxyl groups present in phenolics are good hydrogen donors: 
hydrogen-donating antioxidants, which can react with both reactive oxygen and 
reactive nitrogen species [125-128]. A variety of assays can be employed to 
measure the potential antioxidant and free radical scavenging capacity of 
polyphenolic containing foods. Those assays include:  i) oxygen radical absorbance 
capacity or ORAC, which is based on hydrogen-transfer ability  ii) trolox equivalent 
antioxidant capacity (TEAC) a method based on the scavenging ability of 
antioxidants to the long-life radical anion ABTS•+ and results from test compounds 
are expressed relative to trolox, a water soluble analog of vitamin E and iii) ferric 
reducing antioxidant power (FRAP) based on the ability of a compound  which 
measures reduction of ferric 2,4,6-tripyridyl-s-triazine (TPTZ) to a colored product 
[129]. 
1.8.1. Dietary Flavonoids  
     Flavonoids represent a large class of phenolic compounds found in numerous 
food products such as fruits, vegetables, cocoa, chocolate, tea, red wine, as well as 
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other plant food and beverage products [130].  The Mediterranean Diet (MD) is a diet 
characterized by an abundance of vegetable foods (bread, pasta, vegetables, 
legumes, fruits and nuts) where flavonoids are considered to be important bioactive 
compounds which impart health benefits [131]. In terms of glucose homeostasis, 
experiments performed at both in vitro and in vivo levels demonstrate they can 
regulate carbohydrate digestion, insulin secretion, insulin signaling, and glucose 
uptake in insulin-sensitive tissues by means of several intracellular signaling 
pathways [132]. 
     Regardless of the significant progress obtained in the fields of flavonoid 
bioavailability and their effect at the cellular level, this topic remains a complex one. 
Part of the problem arises from the fact that these dietary compounds are not drugs 
that possess clear pharmacokinetics and pharmacological targets [133]. 
     Flavonoids are only moderately bioavailable and highly metabolized by 
intestinal, hepatic and bacterial cells and considered to be fairly reactive due to their 
phenolic nuclei which grants them a reducing character as well as affinity for 
proteins[133]. 
      After the ingestion of red raspberries (RR), for instance, the polyphenols are 
at least partially bioavailable to systemic organs, through absorption, distribution, 
metabolism and excretion (ADME) [134]. Anthocyanins are widely reported to have 
low bioavailability, with most of the studies recording peak plasma concentrations 
(Cmax) ranging from 1 to 120 nmol/L [135] and urinary recoveries < 2% of intake 
[136] [137]. Yet, a recent study shows extensive colonic microbiota mediated 
degradation of 13C5-labeled cyanidin-3-O-glucoside which resulted in the production 
of many phenolic metabolites over a 0-48 h period. The relative bioavailability of the 
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13C5-labeled was 6.9 % in breath as CO2, 5.4 % in urine and 32% in feces in the form 
of 13C5-labeled phenolic and aromatic compounds [138] [139].  
     Regarding ellagitannins and ellagic acid, also very significant polyphenolics in 
RR, their bioavailability is considered to be very low. These molecules are subject to 
extensive metabolism by the gut microbiota to produce urolithins that are much 
better absorbed. Urolithins circulate in plasma as glucuronide and sulfate conjugates 
at concentrations usually ranging from  0.2–20 µM [140]. Hence, it can be implied 
that the health effects of ellagitannin-containing products can be associated with 
these gut-produced urolithins, therefore, evaluation of the biological effects of these 
metabolites is essential [140]. 
      Berries are distinguished from other fruits and vegetables containing 
phenolics by having high concentrations of anthocyanins, with strong antioxidant 
capacities, up to 4 times greater than non-berry fruits and 40 times that of cereals 
[141]. Berries can be considered as small fruits that can be eaten whole and include 
true berries such as black currant, red currant and gooseberry whereas false or 
epigenous berries include cranberry and blueberry.  RR falls within the aggregate 
berries, which also include blackberry and hybrid boysenberry and the multiple berry 
mulberry. 
       RR are becoming more appreciated due to their culinary versatility and 
multiple applications [35] and are singular among berries due to their attractive red 
color, low glycemic index, low caloric value, high dietary fiber, good flavor, and high 
concentrations of hydrolysable and condensed tannins, flavonoids, phenolic acids, 
carotenoids including lutein and zeaxanthin, choline, potassium, and vitamin C and 
K1 [142]. Raspberries place very high when performing assays such as ORAC, 
TEAC and FRAP on the ranking of antioxidant fruits and vegetables. This allows 
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raspberries to be considered as one of the richest sources of dietary antioxidants 
overall [143]. The antioxidant capacity of raspberries is believed to derive from their 
vitamin C (~20%), anthocyanins (~25%)  and ellagitannins (more than 50%) content 
[143]. 
     RR are native to northern North America and Eurasia. Raspberries can be 
easily grown in numerous areas around the world and are relevant in both the fresh 
fruit market and for processing into frozen products, juices or dried fruit. Fruits of the 
raspberry tree are typically red colored but can also be black or yellow. Cultivated 
RR were introduced into the United States as long ago as 1771. RR are the third 
most consumed fresh berries in US households, accounting for ~ 3-4 % of total berry 
production and are considered delicacies which are cultivated to deliver more than 
70 million pounds per year in leading producing regions such as Washington, 
Oregon and California. Raspberries can be consumed raw or as a processed 
(frozen, pureed) ingredient in a number of dishes, sauces, salads, and drinks [35].  
1.8.2. Phytochemical Profile of Red Raspberry 
      Phenolic phytochemicals are abundant in plants and serve a plethora of 
biological functions such as roles in growth and development of the plant and in 
defense mechanisms to counter insects and UV radiation. The phenolic profile in RR 
consists mainly of anthocyanins and hydrolysable tannins.  A serving of fresh RR 
contained the following biologically active compounds [43]: 
(A) Ellagitannins: Sanguiin H-6 and lambertianin C [144] are the major ones. 
Ellagitannins (ETs) are hydrolysable tannins (HTs) which when compared to 
condensed tannins are more stable [43]. Berries are considered to be the major 
contributors to the ET intake in westernized countries [145]. ETs are known to be 
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present in large amounts in berry fruits. Sanguiin H-6 (Figure 1.4.) is the main ET in 
raspberry and strawberry [146]. 
     Ellagitannins are capable of expressing exceptional biological activities such 
as the potentiation of antibacterial activity, the inhibition of mutagenicity off 
carcinogens and tumor promotion, host-mediated antitumor and highly potent 
antiviral effects [147, 148].   
    However, the therapeutic potential of ellagitannins remains unexploited in 
conventional (occidental) pharmaceutical approaches [149, 150] . In vitro, sanguiin 
H-6 has been found to inhibit cell viability in a concentration-dependent manner and 
it increased the rates at which MCF-7 and MDA-MB-231 human breast cancer cells 
underwent apoptosis [151]. An in vitro enzymatic study by McDougall et al. [152] 
strongly suggested that ellagitannins in raspberry were the main active components 
for amylase inhibition, an approach considered to have the potential to be used as a 
therapeutic agent to control non-insulin dependent diabetes mellitus or T2DM. 
     Ellagitannins are not absorbed per se but rather are subjected to the action of 
colonic microbiota which yields ellagic acid which is further converted to urolithins 
and the latter are absorbed into the circulatory system mainly as sulfate and 
glucuronide phase II metabolites [153] [154]. Urolithins and pyrogallol deter the 
formation of advanced glycation end products (AGEs) [155] which are highly 
responsible for diabetes and its complications [156].  
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(B) Proanthocyanidins: Also known as condensed tannins, proanthocyanidins (PA) 
are oligomeric and polymeric flavan-3-ols [157].  
(C) Anthocyanins (ACN):  C3S (Figure 1.5.) and cyanidin-3-glucosyl rutinoside are 
the major ones [158] with some RR varieties having cyanidin-3-glucoside in 
significant amounts.  In general, anthocyanins with more hydroxyl groups or less 
sugar moieties are considered to have greater antioxidant capacity. Alzaid et al. 
[159] performed an in vitro study, which showed that acute exposure (15 min) to 
berry extract (derived from blueberry, bilberry, cranberry, elderberry, raspberry seeds 
and strawberry- 0.125%, w/v- the ACN content consists of cyanidins 44.5%; 
delphinidins 26.1%; petunidins 14.4%; malvidins 8.9%) significantly decreased both 
sodium-dependent (total uptake) and sodium-independent (facilitated uptake) [3H]-
D-glucose uptake in human intestinal Caco-2 cells. 
      In vivo in humans, raspberry ACN are metabolized into phenolic acids such as  
hippuric acid, 4’-hydroxyphenylacetic acid, 3’4’-dihydroxyphenylacetic acid (DOPAC)  
[160] and 4’-hydroxyhippuric acid [161]. Analyses of fecal samples collected over 24 
h in human patients showed that after ingesting 140 µM of cyanidin-3-glucoside 
(C3G), amounts recovered for C3G and protocatechuic acid (PCA)  were 0.28 and 
41.6 µmol, respectively [162].     
Figure 1.4. Chemical structure of the ellagitannin Sanguiin-H6. 
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Figure 1.5. Chemical structure of the anthocyanin cyanidin-3-sophoroside (C3S). 
 
     PCA may help to reduce diabetes development because it can upregulate 
adiponectin and GLUT4 and exert insulin-like activity by activating PPAR-γ in human 
omental adipocytes [163]. When supplementing to mice at 2 % of the diet PCA 
lowered levels of several markers of the disease (plasma C-reactive protein, TNF-α) 
reducing diabetic complications [164].  
(D) Phenolic acids:  Gallic acid (GA) is the major phenolic acid in the group and is a 
trihydroxybenzoic acid. Studies show GA decreases ROS in isolated mitochondria 
[165] and increases antioxidant enzyme activity in a rat kidney model using diazinon 
to induce renal toxicity[166]. Such enzymes include superoxide dismutases, 
glutathione peroxidase (GPx), catalase, glutathione-s-transferase and reduced 
glutathione (GSH). These highlights remark the potential of GA as a redox regulator. 
(E) Quercetin. A flavonol being one of the most abundant polyphenols present in 
fruits and vegetables [167]. The major microbial metabolite of quercetin is 3,4-
dihydroxyphenylacetic acid or DOPAC (Figure 1.6.)   which possesses strong  
antioxidant activity. DOPAC has been shown to have the highest free radical 
scavenging activity when tested in vitro along with other flavonoid metabolites and it 
might also reduce plasma lipid peroxidation in vivo [168, 169]. In a study using Min6 
pancreatic β cells, DOPAC increased Nrf2 translocation to the nucleus and protected 
pancreatic β cells against impaired insulin secretion induced by cholesterol through  
29 
 
prevention of oxidative stress, apoptosis and mitochondrial dysfunction. Their 
findings suggest that DOPAC is a promising drug target for the prevention of 
development from a prediabetic to a diabetic state [170].  
 
Figure 1.6.  Chemical structure of 3,4-dihydroxyphenylacetic acid or DOPAC. 
 
(F) RR also contain  rheosmin or raspberry ketone (4-(4-hydroxyphenyl)-2-butanone) 
which is the key flavor of raspberries and has been extensively used by the food 
industry as flavoring agent and for other purposes in perfumery and cosmetics [171]. 
1.9. Research Objective and Specific Aims 
      The main objective of the clinical study proposed in this project is to 
investigate the protective effect of whole red raspberries (RR) (Rubus idaeus) 
against insulin resistance, oxidative stress, and biomarkers of inflammation in 
prediabetic and type 2 diabetic patients. The in vitro studies will elucidate how 
metabolites from the fruit can effect insulin resistance, oxidative stress and loss of 
cell function. We hypothesized that regular consumption of whole RR will be effective 
in improving insulin sensitivity and reducing islet cell toxicity and inflammation in 
T2DM patients which often accompany this condition.  
     The specific aims were: (1) to determine the efficacy of whole RR against insulin 
resistance and inflammation in prediabetic and T2DM patients. (2) To determine the 
molecular mechanism(s) by which whole RR prevent the destruction of pancreatic β-
cells. 
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CHAPTER 2. EFFECTS OF RED RASPBERRY POLYPHENOLS AND 
METABOLITES ON BIOMARKERS OF INFLAMMATION AND 
INSULIN RESISTANCE IN PREDIABETES AND TYPE 2 DIABETES  
 
2.1 Introduction  
     Berry fruits are excellent sources of various polyphenolic compounds, 
which exhibit anti-oxidative, anti-inflammatory and anti-carcinogenic activities 
[172]. Anthocyanins and ellagitannins are the most abundant polyphenolics 
found in red raspberries (RR) (Rubus idaeus) [2].  RR fruits also contain other 
beneficial compounds such as vitamin C, fiber, phenolic acids and carotenoids 
[172]. Anthocyanins which are responsible for the blue, purple and red color of 
many plants make up the largest and probably the most important group of 
water-soluble plant pigments [173]. Anthocyanins occur naturally in plants as 
glycosides of the anthocyanidin molecule [174]. Multiple health-promoting 
properties are attributed to anthocyanidins including antioxidant activity, anti-
inflammatory activity and anticarcinogenic properties, as well as protection 
against heart disease, and reduction in the risk of diabetes and cognitive 
function disorders [5]. Similar attributes to those of anthocyanidins have been 
observed in ellagitannins and ellagic acid (a tannin and tannin derivative, 
respectively) as well [175]. 
     Diabetes mellitus (DM) which includes type 1 (T1DM) and type 2 
(T2DM) is a noncommunicable and severe endocrine metabolic disorder which 
reduces the ability of cells to uptake glucose and as a result induces serious 
complications in various organs. Diabetes Mellitus is characterized by an 
increase in blood glucose levels due to either deficiency of insulin secretion by 
pancreatic β-cells or inefficiency of cells to use insulin against glucose. Type 2 
diabetes (T2DM) is a serious health threat with global impact that results from 
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a combination of risk factors such as genetic, environmental, and behavioral 
risk factors (diet, lack of exercise) [176]. Type 2 diabetes is considered  a 
chronic inflammatory disease which results in high circulating levels of tumor 
necrosis factor (TNF), interleukins, and adipokines which are released from 
adipose tissue [177]. Additionally, insulin resistance and dysfunctions of 
pancreatic beta cells are primary characteristics of T2DM [178]. IL-1β, a key 
inflammatory mediator during T2DM, promotes insulin resistance, impairs β-
cells function, and causes apoptosis. Reactive oxygen species (ROS) play a 
pivotal role in a variety of processes such as cell proliferation, inflammation, 
apoptosis, immune system and maintenance of redox balance [179]. Over 
accumulation of free radicals and ROS is implicated in the development of 
age-related diseases and chronic disorders such as DM, cancer, 
atherosclerosis, and neurodegenerative disorders [180-182]. In a study 
involving 1997 females from the United Kingdom, higher intake of 
anthocyanins was associated with significantly lower concentrations of high-
sensitivity C-reactive protein (hsCRP), a marker of obesity and diabetes [183].          
      Moreover, a large cohort study of 200,994 health professionals from the 
United States revealed that consumption of anthocyanin-rich foods were 
inversely correlated with the risk of diabetes [184]. Alzaid et al. (2013) [159] 
found that acute exposure to the anthocyanin-rich extract from berry fruits 
significantly decreased both Na+-dependent and Na+-independent glucose 
uptake in Caco-2 cells. 
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     Anthocyanins are widely reported to have low bioavailability, with most 
of the studies recording peak plasma concentrations (Cmax) ranging from 1 to 
120 nmol/L [135] and urinary recoveries < 2% of intake [136] [137]. After the 
ingestion of red raspberries, the polyphenols are partially bioavailable to 
systemic organs, through absorption, distribution, metabolism and excretion 
(ADME) [17].  A recent study shows extensive colonic microbiota mediated 
degradation of 13C5-labeled cyanidin-3-O-glucoside, which resulted in the 
production of many phenolic metabolites over a 0-48 h period. The relative 
bioavailability of the 13C5-labeled was 6.9 % in breath as CO2, 5.4 % in urine 
and 32% in feces in the form of 13C5-labeled phenolic and aromatic 
compounds [138] [139].  Ellagitannins and ellagic acid also exhibit low 
bioavailability. These molecules are subject to extensive metabolism by the 
gut microbiota to produce urolithins that are much more efficiently absorbed.  
     Urolithins circulate in plasma as glucuronide and sulfate conjugates at 
concentrations usually ranging from  0.2–20 µM [140]. Hence, it can be implied 
that the health effects of ellagitannin-containing products can be associated 
with the gut-produced urolithins, therefore, evaluation of the biological effects 
of these metabolites is essential [140]. 
     The aim of the present work was to determine the anthocyanin profile of 
mixed puree containing Meeker, Wakefield and Chemainus red raspberries, to 
measure the level of metabolites in the plasma of T2DM and prediabetic 
patients before and after 2 weeks of RR smoothie consumption, as well as to  
measure the levels of insulin, and glucose intolerance. DOPAC, a metabolite 
of quercetin and anthocyanins, was evaluated in vitro to try to elucidate 
whether it can promote insulin secretion. Pro-inflammatory and anti-
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inflammatory cytokines and biomarkers in the serum of the same group of 
T2DM patients were measured both before and after 2 weeks consuming the 
fruit. 
2.2. Materials and Methods 
2.2.1. Materials  
     Whole raspberries were provided by the National Processed Raspberry 
Council (Lynden, WA). Cyanidin-3-sophoroside (C3S) standard was 
purchased from Indofine (Hillsborough, NJ). HCYTOMAG panels for 13-plex 
Luminex assay were purchased from EMD Millipore (Billerica, MA). Rat insulin 
ELISA kits and oxLDL were purchased from Mercodia (Uppsala, Sweden). 
     Urolithin A glucuronide (Uro-A glur), isourolithin A (IsoUro-A glur), 
urolithin B glucuronide (Uro-B glur), isourolithin A (IsoUro-A), urolithin A (Uro-
A), urolithin B (Uro-B), were chemically synthesized and purified by 
Villapharma Research S.L. (Parque Tecnológico de Fuente Alamo, Murcia, 
Spain). Ellagic acid (EA), 3,4-Dihydroxyphenylacetic acid (DOPAC) and 
protocatechuic acid (PCA)  were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Urolithin A sulfate and urolithin B sulfate were obtained as 
described elsewhere [185]. Stock solutions were prepared in methanol to a 
final concentration of 2000 ppm (11.2 mM). All solutions were stored at −20 
°C. Methanol (MeOH) and acetonitrile were purchased from J. T. Baker 
(Deventer, The Netherlands). Formic acid and acetic acid were from Panreac 
(Barcelona, Spain). Milli-Q system (Millipore Corp., Bedford, MA) ultrapure 
water was used throughout this experiment. All chemicals and reagents were 
of analytical grade. 
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2.2.2. Cell Culture 
     Rat pancreatic β-cells (INS-1), courtesy of Dr. Henrique Cheng at the 
LSU School of Veterinary Science, were used for this study. Cells were 
cultured in RPMI-1640 medium (11 mM glucose and supplemented with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate and 50 
µM 2-mercaptoethanol. The cells were maintained in a humidified atmosphere 
(5 % CO2 at 37 ⁰C) and the experiments performed with cells between 
passages 80 and 82. 
2.2.3. HPLC-PDA-MS Analysis of Anthocyanins  
    To determine the profile and concentration of anthocyanins and 
ellagitannins in liquefied RR, the method of Ludwig et al 2015 (2) was used. 
Briefly, 5 g of thawed RR were homogenized with 15 ml of MeOH/H2O/formic 
acid at 75:25:1 v/v/v and ultrasonicated for 1 h at 5 ºC. Samples were then 
centrifuged for 10 min at 4000 x g and 20 µl of the supernatant were analyzed. 
Anthocyanins were evaluated by reverse phase chromatography using a 
Shimadzu UHPLC-PDA (Nexera-i LC-2040C 3D system) coupled to a 
Shimadzu MS (triple-quadrupole LCMS-8040, LC-MS/MS), a Shimadzu C18 
(50 x 2.1 mm, 1.9 μm) column and solvents A: 4.5% formic acid acidified water 
and B: acetonitrile. Separation was achieved with a flow rate of 0.4 mL/min 
and a gradient of 2% B for 0-1 min, 2-22% B from 1-11 min, 22-40% 11-12 min 
at 40 °C. Twenty μL of each sample was injected for analysis. Spectral data 
was collected using a photodiode array detector from 250-700 nm. Mass 
spectrometry was performed under positive ion mode; data were monitored 
using Q3 total ion scan (SCAN, from m/z 100-1100), and selected ion 
monitoring was conducted for m/z 271, 287, 301, 303, and 331, representing 
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common anthocyanidins [186]. This analysis was performed at The Ohio State 
University (Columbus, OH). 
2.2.4. MALDI/MS Analysis of Ellagitannins 
    For sanguiin H-6, the method of Kahkonen et al., 2012 [187] was used with 
slight variations. Briefly, 100 g of RR was thawed, homogenized, and then mixed 
with 833 ml of 70 % aqueous acetone solution. This mixture was then centrifuged at 
3000 RPM for 15 min. A final volume of ~ 1,666 ml was recovered and placed on a 
rotovapor at 40 ºC to evaporate the acetone portion. A ~ 540 ml volume was 
recovered and freeze-dried. The ellagitannin extract was further purified using 
Amberlite XAD-7 (Fischer Sci, Hampton, NH) column chromatography with 100 ml of  
6% CH3CN (CH3CN:TFA:H2O 6:0.5:93.5 V/V/V) to wash out  free sugars and organic 
and phenolic acids.  
      Elution was continued with CH3CN (CH3CN: TFA 99.5:0.5) to obtain a fraction 
containing flavonols, anthocyanins, and ellagitannins. To separate ellagitannins, a 
column of similar size and packed with Sephadex LH-20 (GE Healthcare, Little  
Chalfont, UK) (3 g) was used. The sample was introduced into the column, and 
flavonols and anthocyanins were eluted with 50% MeOH. Finally, ellagitannins were 
eluted with aqueous acetone (70:30 V/V). A fraction of this was used to do MALDI-
MS analysis.  
2.2.5. Clinical Study Design 
      Seven type 2 diabetic (T2DM) and 2 pre-diabetic subjects on no current 
diabetic treatment between the age of 18 and 70 who were not pregnant or 
nursing a child were enrolled in this study at Pennington Biomedical Research 
Center (PBRC). Subjects taking a medication that affects insulin sensitivity 
were excluded from the study. Subjects taking any anti-inflammatory 
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medications such as naproxen, aspirin, or ibuprofen less than 2 weeks prior to 
first blood test and for duration of study were excluded. Subjects with an 
inflammatory disease were excluded from the study. A finger stick was done to 
confirm fasting blood glucose was between 109 and 200 mg/dL to qualify, or 
have a recorded post-prandial glucose greater than 200 mg/dL. The subjects 
returned on day one (BSL) for an oral glucose tolerance test in which insulin 
and glucose were measured at all-time points (OGTT) (0, 30, 60, 120, and 180 
min), and C-reactive protein (hsCRP) levels were measured at baseline. 
Insulin and hsCRP were measured from serum by chemiluminescent assays  
using an Immulite® 2000 Immunoassay System (Siemens, Munich, Germany). 
In an OGTT, the blood sugar rises and then returns to baseline. People with 
diabetes show a slower return to baseline than people without diabetes. At 
time 0 of the OGTT, 10 cc of blood were drawn and plasma frozen at -70 ºC 
for analysis of metabolites. In addition, blood was drawn for a multiplex 
magnetic bead-based immunoassay. The subjects returned the following day 
for a blood draw. The participants were asked to come to the clinic every day 
for two weeks including weekends to drink one serving (123 g) of a raspberry 
smoothie containing 9.67 % erythritol as sweetener.  Other than the smoothie, 
no dietary changes were made. At the end of the two week feeding (PF), the 
participants underwent another identical OGTT.  
2.2.6. Metabolite Analysis in Plasma  
    Plasma samples were obtained by centrifuging whole blood at 800 x g 
for 10 min at room temperature and was collected and separated into 1 ml 
aliquots and placed at -80 ᵒC until use. Plasma samples were defrosted, 
vortexed and 200 µL were thawed and extracted with 600 µL 
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acetonitrile:formic acid (98:2, v/v) by vortexing for 2 min and ultrasonic bath for 
10 min. Next, the mixture was centrifuged at 14000 x g for 10 min, and the 
supernatant was lyophilized.  
     The lyophilized residue was redissolved in 100 µL of MeOH and filtered 
through a 0.22 µm PVDF filter before analysis by ultra-performance liquid 
chromatography quadrupole time of flight mass spectrometry using 
electrospray ionization (UPLC-ESI-QTOF-MS/MS). This analysis was 
performed at CEBAS-CSIC center in Murcia, Spain. 
      Plasma samples were analyzed using an Agilent 1290 Infinity UPLC 
system coupled to the 6550 Accurate-Mass Quadrupole Time-Of-Flight 
(QTOF) mass spectrometer (Agilent Technologies, Waldbronn, Germany) 
through an electrospray interface with Jet Stream technology. Separation was 
achieved as previously reported [188]. Briefly, a reverse phase column 
Poroshell 120 EC-C18 column (3 × 100 mm, 2.7 µm) (Agilent) operating at 30 
°C was used. The mobile phases were water:formic acid (99.9:0.1 v/v; Phase 
A) and acetonitrile:formic acid (99.9:0.1 v/v; Phase B). Gradient was as 
follows: 0–3 min, 5–15% B; 3–11 min, 15–30%; 11–15 min, 30–50%, 15–21 
min, 50–90%. The flow rate was set constant at 0.4 mL/min and the injection 
volume was 3 µL. The optimal conditions of the electrospray interface were as 
follows: Gas temperature 280 °C; drying gas 9 L/min, nebulizer 45 psi, sheath 
gas temperature 400 °C, sheath gas flow 12 L/min. Spectra were acquired in 
the m/z range of 100–1100, in a negative mode and with an acquisition rate of 
1.5 spectra/s. Internal mass calibration by simultaneous acquisition of 
reference ions and mass drift compensation was used to obtain low mass 
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errors. Data were processed using the Mass Hunter Qualitative Analysis 
software (version B.06.00, Agilent). 
     A target screening strategy was applied to all plasma samples searching 
for a list of target compounds after MS full-acquisition as well as the direct 
comparison with authentic standards was performed. The quantification of 
ellagitannins derived metabolites as well as DOPAC and PCA were 
determined in plasma by interpolation in the calibration curve obtained with 
their own available standards in the plasma matrix. All metabolites were 
quantified in MS by peak area integration of its extracted ion chromatograms. 
2.2.7. Effect of DOPAC on Insulin Secretion 
     INS-1 cells, an insulinoma cell line, were cultured following Suantawee 
et al. [189] method. In brief, cells were cultured on 24-well plates at a density 
of 5 X 105 cells/well. When confluency was achieved following ~ 72 h, the cells 
were incubated for 30 min in modified Krebs-Ringer bicarbonate buffer (KRB) 
containing 136 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 
mM MgSO4, 5 mM NaHCO3, 10 mM HEPES, 4 mM glucose, and 0.1 % bovine 
serum albumin (BSA), pH 7.4. A second incubation was performed for 30 min 
with KRB containing DOPAC at different concentrations (1-100 µM) or 20 mM 
KCl (positive control). After incubation, the supernatant was collected and 
stored frozen at -80 ⁰C for insulin determination with ELISA. 
2.2.8. Analysis of Levels of Inflammatory Cytokines in Serum 
      The levels of pro-inflammatory and anti-inflammatory cytokines in 
serum including interleukin1 beta (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL-
4), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 
12p70 (IL-12p70), interleukin 13 (IL-13), interferon gamma (IFN-γ), 
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granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 alpha 
(MIP-1A), tumor necrosis factor alpha (TNF-α), and plasminogen activator 
inhibitor-1 (PAI-1) were measured by a multiplex magnetic bead-based 
immunoassay (Luminex®) system. This analysis was performed at PBRC 
using a Luminex 200 (Luminex Co., Austin, TX).  Oxidized Low density 
lipoprotein (oxLDL) was measured by ELISA using plasma. 
2.2.9. Statistics 
     Results are expressed as means ± SD with the exception of AUC 
curves for diabetics which were expressed using standard error of the mean 
(S.E.M). Differences between weeks were analyzed by paired t-test whereas 
levels of inflammatory cytokines in serum were analyzed using Wilcoxon 
signed rank test using SAS 9.4 (SAS Institute, Cary, NC). Results for insulin 
secretion were expressed as mean ± S.E.M from two independent 
experiments, each experiment having n=6. Basal control and the different 
DOPAC concentrations were compared using unpaired student t-test using 
GraphPad Prism v8.0 (GraphPad Software, San Diego, CA). Significance was 
taken at p < 0.05. 
2.3. Results 
2.3.1. Quantitative Analysis of Cyanidin-3-Sophoroside (C3S) in Raspberry 
Purée 
 
      C3S, an anthocyanin and one of the bioactive compounds of interest 
was analyzed to determine anthocyanin profile by UHPLC-PDA-MS. C3S with 
79% area under the peak (AUP), cyanidin-3-glucoside (15% AUP), and 
cyanidin-3-sambubioside (4% AUP) were the major anthocyanins identified by 
PDA/MS-MS  data and by comparison to literature at  520 nm  ([190] [191]) 
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(Figure 2.1.). Small traces of additional anthocyanin derivatives, tentatively 
assigned identities of pelargonidin, peonidin and malvidin, accounted for the 
remaining percentage area under the peak of the pigments, but were not 
clearly identified due to presence of co-eluting compounds (Table 2.2.). These 
peaks were assigned aglycone identities based on select ion monitoring. 
     Quantitative values of the anthocyanins in the extracts were calculated 
after production of a standard curve using a standard of C3S as a reference 
material. The curve showed a good fit by linear regression (R2 = 0.9964) with 
injections of C3S amounts of 0.1 – 10 μg. Anthocyanin concentrations of the 
extracts were determined to be a total of 887.6 ± 262.8 μg/g C3S equivalents, 
as determined by a HPLC calibration curve (detection at 520 nm, Table 2.2.). 
The most prevalent anthocyanin of the extracts was C3S (626.0 ± 179.8 µg/g), 
accounting for the majority of the total anthocyanins. 
2.3.2. Qualitative Analysis of Ellagitannins in RR 
      Raspberry extraction of ellagitannin compounds including casuarictin (936.64 
M.W.), sanguiin H-6 (1871.27 M.W.) and lambertianin C (2,805.81 M.W.) was 
performed. These polyphenols are responsible for some of the beneficial health 
effects in raspberry [192-194], and were analyzed by MALDI-MS. Results showed 
strong peaks for two of these compounds which corresponded to sanguiin H-6 
(1893.22 M.W.) being the highest followed by lambertianin C (2,827.25 M.W.) 
(Figure 2.2.). Quantification of these compounds in the extract was not performed 
due to lack of a standard for sanguiin H-6, therefore this analysis covered the 
qualitative aspect only. 
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Figure 2.1. UHPLC chromatogram of RR extract compounds, detection at 520 
nm with the six peaks identified and 260-700 nm (max plot). 
 
2.3.3. Baseline Characteristics of the Study Participants 
    Samples from ten patients who successfully completed the study were 
collected and plasma, serum and PBMCs extracted from peripheral blood, 
however one of them was determined to be a type 1 diabetic and was, 
therefore, excluded from the study. Out of the 9 patients left, 7 were type 2 
diabetic and 2 pre-diabetic based on their fasting glucose values during 
screening. Table 2.3. lists the anthropometrics of the participants and results 
observed between test day 1 (BSL) and test day 2 (PF). Values for HOMA-IR 
and hsCRP decreased on PF for the type 2 diabetics after 2 weeks of feeding 
with the reduction having statistical trend for HOMA-IR (p=0.0584) and 
statistical significance for hsCRP (p=0.01). Values for HOMA-IR and hsCRP 
numerically increased on PF in the pre-diabetic group, but with only 2 subjects 
further studies are needed to judge significance.  Glucose at 0 min on the 
OGTT increased in both groups, but the area under the curve (AUC) was 
1,243 ± 878.97 mg/dl/minute less on PF for the type 2 diabetics and 2,497.5 ± 
 
                              1   234     5 6 
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1,766 mg/dl/minute less on the pre-diabetics, yet, neither difference was 
significant (Figures 2.3.A and 2.3.B). AUC analysis for insulin was 1,842.3 ± 
1,302.7 µU/ml/minute less on PF for the type 2 diabetics and 534.8 ± 378.1 
µU/ml/minute more on the pre-diabetics, yet, neither difference  was 
significant, but with a statistical trend at 0 minutes for the diabetic group 
(p=0.0759) (Figures 2.3.C and 2.3.D). In the diabetic group, HOMA-IR and 
hsCRP were calculated with n=7 and n=6, respectively, since one patient had 
an infection and the hsCRP value was a statistical outlier. For the pre-
diabetics, HOMA-IR and hsCRP were calculated with n=2 and n=1, 
respectively, since one of the patients had a high hsCRP value, so statistical 
significance could not be determined.    
2.3.4. Metabolite Analysis in Plasma  
  Two urolithin conjugates, i.e. urolithin A glucuronide (Uro-A glur) and 
urolithin A sulfate (Uro-A sulf) were identified and quantified in 7 patients (n=5 
for diabetics and n=2 for pre-diabetics) at PF but not BSL, indicating they were 
derived from RR smoothie feeding (Table 2.5.). Uro-A glur and Uro-A sulfate 
were quantified after consumption at PF in the range of high and low nM 
range, respectively (Table 2.5.). Uro-A sulfoglucuronide was also identified but 
not quantified, (because no standard was available), in the samples PF of 6 
subjects (n=5, diabetics and n=1, prediabetic).  
      In these patients no other urolithin conjugates such as Uro-B or IsoUro-
A glur were found suggesting a metabolism of ellagitannins according to their 
metabotype A  [195]. Therefore, among 9 patients, IsoUro-A glur and its 
sulfate derivate were identified and quantified in only one of the diabetic 
patients, suggesting metabolism of ellagitannins according to their metabotype 
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B [195]. Uro-B sulfate was also identified in the PF samples of this diabetic 
patient. Finally, no urolithin conjugates were identified in a different diabetic 
patient; however, dimethyl ellagic acid (DMEA) glucuronide was identified but 
not quantified in this patient suggesting a lack of metabolism of ellagitannins 
(metabotype 0). DMEA glucuronide was also found in the PF samples of one 
of the pre-diabetic patients. 
      All urolithin conjugates were quantified above the limits of detection 
(LOD) and quantification (LOQ) previously reported in García-Villalba et al. 
[196]. Moreover, high concentration (low µM range) of DOPAC and PCA were 
identified and quantified in all volunteers of both BSL and PF samples (before 
and after RR intake, respectively). However, no significant differences were 
found over the course of the study. Figure 2.5. shows structures for the 
metabolites found at highest concentrations. 
2.3.5. DOPAC and Insulin Secretion 
      Incubation with KRB containing DOPAC from 1-100 µM did not stimulate 
insulin secretion from INS-1 cells. Decreases were observed on all treatments  
with those at 1 and 3 µM not being significant, yet those at 10, 30 and 100 µM 
had statistically significant decreases (Figure 2.6.). The only significant 
increase was elicited by 20 mM KCl (positive control) with a 2.6-fold increase 
over basal. 
2.3.6. Levels of Inflammatory Cytokines in Serum 
     Table 2.6. lists results for multiplex magnetic bead-based immunoassay. 
Levels on 7 cytokines (IL-1β, IL-2, IL-4, IL-6, IL-12p70, IL-13, and GM-CSF) 
were not determined as they were beneath the LOD. Increases and decreases 
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were observed on the rest of cytokines analyzed on both T2DM and pre-
diabetic patients but none were statistically significant.    
2.4. Discussion 
      The quantification of total ACN in the RR purée extract yielded 88.8 ± 
26.3 mg/100g of fresh fruit of which 91.9% or 81.7 ± 23.7 mg/100 g 
corresponded to cyanidin-based ACN content. This is in agreement with Wu et 
al. [197] who found 90.2 ± 19.2 mg/100 g cyanidin-based ACN content and 
total ACN of 92.1 ± 19.7 mg/100 g when measuring ACNs in 5 different RR 
samples by means of HPLC-DAD-ESI/MS/MS. The high standard deviation 
observed could be explained by potential heterogeneous distribution of the 3 
varieties that constituted the analyzed sample. 
 
Figure 2.2. Results for ellagitannin extract using MALDI-TOF. Major peaks 
corresponded to sanguiin H-6 (1893.22 M.W.) and lambertianin C (2,827.25 M.W.). 
 
 
 
 
 
 Sanguiin H-6 
 Lambertianin C 
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Table 2.1. Concentration (µg/g of C3S equivalent) of anthocyanins in red raspberry 
extract identified and quantified by UHPLC-PDA-QQQ. 
Peak             Identity                       m/z            Mean (µg/g)          Per serving (123 g) 
   1   Cyanidin-3-sophoroside        611/287    626.0 ± 179.8            77.0 ± 22.1 mg                                      
   2   Cyanidin-3-glucoside            449/271    143.2 ± 44.8              17.6 ± 5.5 mg 
   3   Cyanidin-3-sambubioside      581/287      44.1 ± 13.0               5.4 ± 1.6 mg 
   4   Pelargonidin-derivative          595/271     23.8 ± 8.5                  2.9 ± 1.0 mg  
   5   Peonidin-derivative                301             24.2 ± 8.3                  3.0 ± 1.0 mg              
   6   Malvidin-derivative                 301             26.3 ± 8.4                  3.2 ± 1.0 mg        
       Total anthocyanins                                     887.6 ± 262.8         109.1 ± 32.2 mg   
 
Values are means ± SD, n=3                
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Table 2.2. Results for baseline and post-feeding characteristics of the study participants. 
                                                                   Type 2 Diabetics (n=7)                              Prediabetics (n=2) **        
Race (African American/Caucasian) n/n                3/4                                                           1/1                             
Gender (male/female) n/n                                      2/5                                                            0/2 
Age, y                                                                  60.9 ± 9.0                                                   63.0  
Body weight, kg                                                 103.0 ± 16.2                                                101.1      
BMI, kg/m2                                                            37.2 ± 6.3                                                   38.6  
Systolic blood pressure, mm Hg                        132.6 ± 11.3                                                 124.5                            
Diastolic blood pressure, mm Hg                        86.7 ± 8.2                                                     71.0  
Fasting glucose, mg/dL                                      170.0 ± 27.8                                                 109.0  
OGTT glucose (time 0), mg/dL                 BSL: 161.6 ± 32.0   PF: 164.0 ± 38.5                  BSL: 93.0   PF: 100.0  
HOMA-IR                                                  BSL: 13.3 ± 7.3       PF: 9.4 ± 5.4                        BSL: 6.0     PF: 8.5  
hsCRP, mg/L (n=6, T2DM and n=1, PD)  BSL:  4.9 ± 2.0      PF: 4.0 ± 1.6*                        BSL: 5.6     PF: 6.1 
All results are expressed as the mean ± SD. Statistical analyses were performed using a paired t-test to detect differences between 
BSL and PF. OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high 
sensitivity C-reactive protein. HOMA index was calculated with the formula: HOMA= [serum glucose levels (mg/dl) X insulin levels 
(µU/ml)/22.5. * p = 0.01. ** No statistics done due to small numbers. 
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Figure 2.3. Effects of RR smoothie consumption on blood glucose and insulin levels 
after oral glucose tolerance test on day 1 (BSL) and day 2 (PF). Results are 
expressed as the mean ± S.E.M. Statistical analyses were performed using paired t-
test. (A) Glucose tolerance test curve for T2 diabetic patients (n=7). (B) Glucose 
tolerance test curve for pre-diabetic patients (n=2). (C) Glucose tolerance test curve 
for insulin in T2 diabetic patients (n=7). (D) Glucose tolerance test curve for insulin in 
pre-diabetic patients (n=2). * No statistics done due to small numbers. 
 
     Because PBMCs contain several key inflammatory cells, higher levels of 
insulin resistance and inflammatory biomarkers at the baseline for T2 diabetic 
and pre-diabetic patients were expected to be present.  
      IR constitutes a crucial factor in the development of type 2 diabetes 
along with hypertension  and cardiovascular (CV) disease [198]. Results 
indicated significant (inflammatory biomarker such as hsCRP) and non-significant 
reductions (glucose AUC, insulin resistance through HOMA-IR) after two weeks of 
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RR smoothie consumption. Stull et al. [199] found that consuming a smoothie 
containing blueberries for 6 weeks had a greater increase in insulin sensitivity in 
obese and insulin-resistant adults (prediabetics, accounting for 67%) when 
compared to individuals that consumed a placebo smoothie (41%) and was 
measured by a 10 % or greater favorable change in insulin sensitivity. For this study 
researchers used the hyperinsulinemic-euglycemic clamp (HEC) to assess insulin 
sensitivity. Even though HEC is considered the “gold standard”, HOMA-IR has 
proved to be a powerful proxy to assess IR [200, 201]. In our study, HOMA-IR had a 
p value of 0.0584 resulting in a statistical trend but not statistical significance. AUC 
analysis for both glucose and insulin showed decreases on PF day, but these were 
not statistically significant on either group. Losso et. al [202] reported that one 
feeding of two slices of  fenugreek enriched bread (5%)  to a group of eight T2DM 
patients yielded a significant reduction in AUC for insulin when compared to bread 
with no fenugreek fed to the same group. RR constitutes a high source of fiber 
providing 8 g per 123 g of fruit [145]. Zhao et al. 2018 [203] identified short chain 
fatty acid (SCFA) - producing bacterial strains who were promoted by dietary fibers. 
In their study, most other potential producers were present at either decreasing or 
not changing numbers in patients with T2DM. Researchers found that when the 
fiber-promoted SCFA producers were present in higher number, participants had 
better improvement in hemoglobin A1c levels. This was attributed in part due to 
increased glucagon-like peptide-1 production. SCFAs such as acetate and butyrate 
have demonstrated the ability to improve glucose homeostasis through production of 
glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), which can stimulate insulin 
secretion [204-206].           
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      However, based on the results obtained through HOMA-IR in the present 
study, insulin secretion in patients was reduced favoring an insulin sensitivity effect. 
This finding could indicate this insulin sensitivity effect could be elicited by other 
molecule in the fruit or perhaps, other metabolite(s). 
     Serum concentration of CRP is increased in both impaired glucose tolerance 
(IGT) and T2DM [207, 208]. Based on numerous studies, minor CRP elevation 
(hsCRP) has been shown to be associated with future major CV risk (hsCRP: <1 
mg/L = low risk; 1–3 mg/L = intermediate risk; 3–10 mg/L =high risk; >10 mg/L _= 
unspecific elevation) [209]. A decrease from 4.9 ± 2 on BSL to 4.0 ± 1.6 on PF was 
registered in our study and found to have statistical significance on T2DM patients 
(p= 0.01).   
    The metabolite analysis found two urolithin conjugates, i.e. urolithin A 
glucuronide (Uro-A glur) and urolithin A sulfate (Uro-A sulf) which were found 
in 7 of the 9 patients’ (both groups) samples, but only for PF indicating they 
were derived from RR smoothie feeding. These were metabolites from the 
ellagitannin portion of the fruit, whereas anthocyanin-derived metabolites such 
as DOPAC and PCA were present at similar concentrations on BSL and PF 
suggesting these metabolites might have come from different dietary sources 
as well. 
     An increase in IL-10 after two weeks of raspberry consumption was 
expected but cytokine analysis by multiplex magnetic bead-based 
immunoassay found the opposite. Increases and decreases were observed on 
the rest of cytokines analyzed, yet, none of these changes were statistically 
significant.  
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     Interpatient variability was observed in plasma metabolite analysis as 
well as for other biomarkers and this could be due to differences in diets, 
individual microbiota or potential effects of erythritol used as non-caloric 
sweetener.  
     From the 9 patients evaluated in the study, six presented a urolithin 
metabotype (UM) A (urolithin A producers only), two (men both) a UM-B 
(production of urolithin A, isourolithin A and/or urolithin B) and one a UM-0 
(urolithin non-producers). Cortés-Martín et al. [210] proposed that aging is the 
main factor affecting the distribution of urolithin metabotypes when they 
evaluated a cohort of n=839, from 5-90 yrs of age. Besides this, the 
researchers described a progressive increase for UM-B parallel to a decrease 
in UM-A, especially for individuals aged 20-40, and when considering a group 
of n=23 patients aged 30-63 who suffered from metabolic syndrome, both UM-
A and UM-B had a similar share.  In the present study, however, the 
dominating UM was UM-A, therefore, it is important to highlight their cohort 
consisted mainly of caucasian individuals only whereas in the present study 
African  Americans constituted 44.4 % of the patients evaluated, the rest 
(56%) being Caucasian. Gonzalez-Sarrías et al.[211] observed that 
overweight–obese individuals with UM-B were at higher CVD risk than those 
with UM-A or UM-0, hence, the UM-A preponderance among the patients from 
our clinical trial could be taken as a positive outcome.   
      Regarding potential mechanisms of anti-diabetic properties of whole RR 
observed in patients from the clinical trial, Edirisinghe & Freeman [212], list two ways 
these can be addressed: insulin dependent and insulin independent. Within insulin 
dependent, an insulin sensitivity enhancement was observed judging by the drop on 
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insulin and hsCRP, an important biomarker of inflammation and CVD risk [213].  
Assessment of the metabolite DOPAC (1-100 µM) to investigate if it could elicit 
insulin secretion on INS-1 cells showed the opposite, an even had a toxic 
effect at higher concentrations. This finding is congruent with what was 
observed on the clinical trial patients as insulin and glucose levels dropped by 
PF day indicating an improvement in insulin sensitivity. Work by other 
researchers has demonstrated stimulation on insulin secretion by compounds 
such as quercetin [115, 214] and cyanidin [189] when used at levels ranging 
from 20-100 µM. These concentrations, however, may not be feasible at 
physiological levels due to metabolic availability and toxicological issues.         
     Researchers described activation of the extracellular signal-regulated 
kinase (ERK) 1/2 pathway and L-type voltage-dependent Ca2+ channel 
(VDCC) in INS-1 cells as responsible for increases in insulin secretion. For the 
insulin independent part, both inhibition of digestive enzymes involved in 
carbohydrate breakdown as well as inhibition of glucose absorption in the GI tract 
can be present, however in the present study a minor increase in glucose from 
OGTT at 0 min on PF was observed yet non-significant reductions on the AUC for 
OGTT on both T2DM and prediabetics were present on PF. Work performed by 
other researchers highlights these findings.  
     Edirisinghe & Freeman, found when overweight adults were fed a 
freeze-dried strawberry powder that it significantly reduced postprandial insulin 
response and reduced  postprandial inflammatory  response (IL-6 and hsCRP) 
when the participants ate a high carbohydrate and high fat meal (P < 0.05) 
[212]. Alzaid et al., 2013 [159] used a berry extract containing raspberry seed 
and were able to significantly decrease both sodium-dependent intestinal cell 
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(total uptake) and sodium-independent [3H]-D-glucose uptake in human 
intestinal Caco-2 cells. Treatment for 16 h showed SGLT1 mRNA and GLUT2 
mRNA expression was significantly reduced (P < 0.05.) Moreover, McDougall 
et al. [215] observed amylase was inhibited when performing an in vitro 
enzymatic study using raspberry. They concluded that ellagitannins in 
raspberry were the main agents for this inhibition, which indicates these 
polyphenols in RR can promote beneficial effects just like the anthocyanin 
fraction does.     
2.5. Conclusion 
     Two urolithin conjugates,   (Uro-A glur and Uro-A sulf) were found in 7 of 
the 9 patients’ plasma samples at nanomolar concentrations (1.3 - 63.2 ± 31.2 
nM, Table 2.5.), whereas anthocyanin-derived metabolites such as 
protocatechuic acid (PCA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were 
present at micromolar concentrations yet at similar levels on BSL (PCA= 0.5 ± 
0.14, DOPAC= 1.4 ± 0.28) and PF (PCA=0.6 ± 0.07, DOPAC= 1.7 ± 0.8). 
Other metabolites were present in only some of the patients, illustrating that 
each individual’s microbiome, ethnicity, age, etc., most likely plays a role on 
the outcome of such metabolites. Results indicated a significant reduction in 
hsCRP (BSL:  4.9 ± 2.0, PF: 4.0 ± 1.6 (p=0.01)) which is a very important 
biomarker of inflammation and heart disease risk. A reduction showed only a 
statistical trend for HOMA-IR when evaluating for IR. DOPAC, a metabolite 
from anthocyanin and quercetin in RR, when incubated at 1-100 µM did not 
stimulate insulin secretion in INS-1 cells. A longer feeding period with a larger 
group is recommended to test if the effects observed can be improved. This 
study demonstrated the potential of RR to modulate levels of biomarkers of 
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inflammation and insulin resistance in T2DM patients most likely through 
antioxidant activity from the polyphenolics present and from anti-diabetic 
effects through insulin dependent mechanisms. 
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Table 2.3. Results from plasma analysis for raspberry metabolites by UPLC-ESI-QTOF-MS/MS 
                                            Uro-A-Glur α     Uro-A-Sulf α     Iso-Uro-A α     Iso-Uro-A Sulf α    Uro-B- Sulf α        PCAb      DOPACb 
Diabetics (n=7) 
 
BSL                                         ---                       ---                 ---                         ---                      ---               0.6 ± 0.4c     1.2 ± 0.5c 
PF                                     63.2 ± 31.2d        7 ± 4.2d            37.4 ± 1.1f        11.1 ± 0.6f             1.6 ± 0.7f        0.6 ± 0.4c      1.1 ± 0.6c          
 
Pre-diabetics (n=2)*                                                                                                
BSL                                            ---                   ---                  ---                       ---                        ---                        0.4e       1.6e                                         
PF                                        10.3e                    1.3e                ---                       ---                        ---                        0.5e       2.2e 
 
All results are expressed as mean ± SD. Uro-A-Glur, urolithin-A-glucuronide; Uro-A-Sulf, urolithin-A-sulfate; Iso-Uro-A, isourolithin-
A-glucuronide; Iso-Uro-A Sulf, isourolithin-A-sulfate; Uro-B- Sulf, urolithin-B-sulfate; PCA, protocatechuic acid (3,4-ihydroxybenzoic 
acid); DOPAC, 3,4-dihydroxyphenyl acetic acid. 
α
, nanomolar; 
b
, micromolar; ---, not detected;
 c
, detected in n=7; 
d
, detected in 
n=5; 
 e
, detected in n=2; 
 f
, detected in n=1. Compounds urolithin-A- sulfoglucuronide (n=5, diabetics and n=1 pre-diabetics] and 
dimethyl ellagic acid (n=1 for both diabetics and pre-diabetics ; both not listed in the  table)  were detected but not quantified on the 
PF day. * No statistics done due to small numbers.                             
     
 
. 
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Table 2.4. Serum and plasma biomarkers results (pg/ml) by multiplex magnetic bead-based immunoassay and ELISA. 
                                        IL-8              IL-10             IFN-γ        TNF-α               MCP-1                MIP-1α            PAI-1             oxLDL β                  
Diabetics (n=7) 
 
BSL                            7.5 ± 2.9       8.1 ± 5.3      7.8 ± 4.3    15.9 ± 1.4    783.7 ± 211.3    3.8 ± 0.7        132.7 ± 20.7      75.4 ± 19.7    
PF                              7.7 ± 2.3        7.5 ± 4.1      7.7 ± 3.3     15.4 ± 1.3    827.6 ± 282.4      4.2 ± 0.7       133.1 ± 32.2      78.1 ± 20.2              
 
Pre-diabetics (n=2)*                                                                                                
BSL                               17.8            8.3                11.9 #             13.4          1148.5                     19                126.7                  43.8     
PF                                14.9             7.9                  8.2 #             11.6          1054.5                     17.8             103.2                  44        
 
 
All results are expressed as mean ± SD. Data was analyzed using Wilcoxon signed rank test. #, n=1; β, oxLDL assay performed 
through ELISA using plasma samples. * No statistics done due to small numbers.                             
     
 
  
 
56 
 
 
Figure 2.4. Structures of most abundant metabolites from both ellagitannins and 
anthocyanins in RR found in the plasma of clinical trial participants after 2 weeks of 
smoothie feeding. 
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Figure 2.5. Treatment of INS-1 cells with 1-100 uM DOPAC. Results are expressed 
as mean ± S.E.M. from two independent experiments, each experiment having n=6; 
* p < 0.05 when compared with basal. 
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CHAPTER 3. CONCLUSIONS AND FUTURE WORK 
     It has been well established that edible berries are an excellent source of various 
polyphenolic compounds, which exhibit anti-oxidative, anti-inflammatory and 
anticarcinogenic activities [172]. The purpose of this study was to evaluate the potential 
of whole RR to modulate IR and inflammation in T2DM patients. Results from the 
clinical trial showed a significant downregulation of hsCRP, an important biomarker of 
inflammation and CV risk, and an improvement on insulin sensitivity based on HOMA-IR 
results which showed a statistical trend. These results confirm the potential that RR has 
to modulate IR and inflammation and we hypothesize that a longer feeding period  may 
yield better and more representative results that could lead to further downregulation of 
both IR and inflammation biomarkers in T2DM patients. A trial involving more patients is 
recommendable too as a larger sample size would be more representative of the effects 
RR consumption may have and would better evaluate interpatient variability that is 
normally observed in clinical studies of this kind.  Another aim was to determine the 
molecular mechanism(s) by which whole RR prevent the destruction of pancreatic β-
cells. To determine if DOPAC, a metabolite of anthocyanin and quercetin, had insulin 
secretion effects in vitro, an ELISA for insulin secretion using rat pancreatic β-cells (INS- 
1) showed DOPAC did not stimulate insulin secretion at physiologically observed 
concentrations or even at higher non-physiological concentrations. An assay evaluating 
human β-cells is recommended to confirm these results. However, this finding 
complements the insulin sensitivity improvement rather than insulin secretion 
enhancement found in the patients from the clinical trial. It is possible that this effect of 
insulin sensitivity improvement may have derived from other molecules present in RR.  
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   For instance ellagitannins, which were not evaluated in the present study due to 
lack of proper standards for sanguiin H-6, the major ellagitannin present in RR may 
have played a role The major ellagitannin-derived metabolites found in plasma of 
patients such as Uro-A-glur and Uro-A- sulf could have also played a role. 
    Therefore, studies that evaluate the effect(s) of these particular compounds may 
help elucidate the exact mechanism(s) being triggered to yield insulin sensitivity 
improvement through RR consumption.   
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